Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457444 | 0.88 | PDE10A (0.45) | PDE10AALDH1A1POLBCHRM1MAPT | |
| SCHEMBL2454164 | 0.81 | MTNR1A (0.62) | EGLN3PDE10AALDH1A1POLBCYP2D6 | |
| SCHEMBL2286845 | 0.80 | MPO (0.50) | EGLN3PDE10AALDH1A1POLBCYP2D6 | |
| SCHEMBL1960064 | 0.77 | MTNR1A (0.62) | ALDH1A1POLBNPC1RAB9AKDM4E | |
| SCHEMBL29549275 | 0.71 | EGLN3 (0.65) | EGLN3PDE10AALDH1A1POLBCHRNA7 | |
| SCHEMBL2461805 | 0.71 | MTNR1A (0.51) | PDE10AALDH1A1POLBMAPTPLAUR | |
| SCHEMBL2282109 | 0.70 | MPO (0.58) | PDE10A | |
| SCHEMBL230157 | 0.69 | POLB (0.84) | PDE10APOLBCHRM1NPC1RAB9A | |
| SCHEMBL2454014 | 0.69 | KLK7 (0.46) | ALDH1A1POLBNPC1RAB9AKDM4E | |
| SCHEMBL5864478 | 0.69 | ALDH1A1 (0.64) | EGLN3PDE10AALDH1A1POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | EGLN3 1401/4885PDE10A 1133/4885ALDH1A1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.